JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

ESPERION THERAPEUTICS INC

Suletud

SektorTervishoid

2.7 1.5

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.7

Max

2.75

Põhinäitajad

By Trading Economics

Sissetulek

28M

-13M

Müük

17M

82M

Kasumimarginaal

-15.446

Töötajad

304

EBITDA

37M

16M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+155.35% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

358M

653M

Eelmine avamishind

1.2

Eelmine sulgemishind

2.7

Uudiste sentiment

By Acuity

50%

50%

147 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

ESPERION THERAPEUTICS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. okt 2025, 14:47 UTC

Suurimad hinnamuutused turgudel

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

Võrdlus sarnastega

Hinnamuutus

ESPERION THERAPEUTICS INC Prognoos

Hinnasiht

By TipRanks

155.35% tõus

12 kuu keskmine prognoos

Keskmine 6.92 USD  155.35%

Kõrge 16 USD

Madal 1.6 USD

Põhineb 5 Wall Streeti analüütiku instrumendi ESPERION THERAPEUTICS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

4

Osta

0

Hoia

1

Müü

Tehniline skoor

By Trading Central

0.85 / 1.05Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

147 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
help-icon Live chat